The Australian Government Rebate on Private Health Insurance (PHI) for Natural Therapies review.
The Australian Government’s Department of Health and Ageing (DHA ) informed us of the National Health and Medical Research Council’s (NHMRC) review on 26th November 2012, and gave us a short time to produce a submission that covered the underpinning evidence base of clinical efficacy, cost effectiveness, safety and quality of homœopathy, so that homœopathy could remain as a rebate-able service with the PHI funds. This Submission request came after the NHMRC had already set up a working committee; the Homœopathy Working Committee (HWC), which will inform the Natural Therapies Review Advisory Committee (NTRAC) about homœopathy.
To put a very complicated situation into a nutshell it seemed that homœopathy was targeted for special review/treatment, in what looks like a very concerted effort to remove homœopathy from rebate-able PHI fund status. This was on top of the fact that the NHMRC has said that homœopathy was ‘unethical’ in a leaked draft document in 2011, which they had to retract. Nevertheless, the NHMRC Review’s special treatment of homœopathy seemed to indicate a prejudgement on the fate of homœopathic PHI rebates in Australia that would affect your income and your client’s ability to claim rebates on homœopathic services.
We have been working very hard to produce a submission for presentation to the NHMRC to show that homœopathy is not only cost effective and safe but also has a long history of clinical efficacy based on research and evidence.
On the 1st of May AROH was given the opportunity to present the case for homoeopathy to the NHMRC. The presentation took place in Canberra and was attended by Snehi Jarvis (President of AROH) and Ana Lamaro (on behalf of the AHA).
Full copies of the submission can be downloaded below: